Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Allergol Int ; 72(3): 394-401, 2023 Jul.
Article in English | MEDLINE | ID: covidwho-2283131

ABSTRACT

BACKGROUND: The considerable prevalence and worse outcomes of asthma-COPD overlap (ACO) in COPD have been reported, and optimal introduction of ICS is essential for ACO. However, diagnostic criteria for ACO consist of multiple laboratory tests, which is challenging during this COVID-19 era. The purpose of this study was to create a simple questionnaire to diagnose ACO in patients with COPD. METHODS: Among 100 COPD patients, 53 were diagnosed with ACO based on the Japanese Respiratory Society Guidelines for ACO. Firstly, 10 candidate questionnaire items were generated and further selected by a logistic regression model. An integer-based scoring system was generated based on the scaled estimates of items. RESULTS: Five items, namely a history of asthma, wheezing, dyspnea at rest, nocturnal awakening, and weather- or season-dependent symptoms, contributed significantly to the diagnosis of ACO in COPD. History of asthma was related to FeNO >35 ppb. Two points were assigned to history of asthma and 1 point to other items in the ACO screening questionnaire (ACO-Q), and the area under the receiver operating characteristic curve was 0.883 (95% CI: 0.806-0.933). The best cutoff point was 1 point, and the positive predictive value was 100% at a cutoff of 3 points or higher. The result was reproducible in the validation cohort of 53 patients with COPD. CONCLUSIONS: A simple questionnaire, ACO-Q, was developed. Patients with scores ≥3 could be reasonably recommended to be treated as ACO, and additional laboratory testing would be recommended for patients with 1 and 2 points.


Subject(s)
Asthma , COVID-19 , Pulmonary Disease, Chronic Obstructive , Humans , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/epidemiology , Asthma/diagnosis , Asthma/epidemiology , Dyspnea , Surveys and Questionnaires , COVID-19 Testing
3.
COVID-19 viral pneumonia risk factor acute respira ; 2020(The Journal of the Japanese Association for Infectious Diseases)
Article in Japanese | WHO COVID | ID: covidwho-723335

ABSTRACT

We report the case of an 85-year-old woman who was transported to our hospital by ambulance with progressively worsening dyspnea and hypoxia. She had no history of contact with any patient with coronavirus disease 2019 (COVID-19). The peripheral arterial oxygen saturation level on a 10 L/min non-rebreather-type mask was as low as 80%. Chest auscultation revealed coarse crackles. After emergency intubation, it was surmised that the probability of heart failure was low because of the lack of pink, frothy sputum. Bacterial pneumonia was also considered to be unlikely, as the sputum was not purulent. Moreover, laboratory data revealed a normal white blood cell count (6,100/μL) and no elevation of the serum procalcitonin level (0.63 ng/mL), which were also consistent with the condition not likely to be a bacterial infection. Pulmonary thromboembolism was ruled out by the presence of coarse crackles on chest auscultation and normal blood pressure. Thereafter, the possibility of COVID-19 was considered and the patient was immediately isolated. Two days later, the polymerase chain reaction test for COVID-19 returned positive. There was no evidence of transmission of the virus to the healthcare personnel who had treated this patient, including the 6 with medium-risk exposure, during the 3-week period after the exposure. In the COVID-19 pandemic era, rapid differential diagnosis of hypoxia is essential to prevent further transmission of SARS-CoV-2 infection. Our case highlights the importance of the sputum appearance/characteristics and laboratory data for rapidly ruling out diseases other than COVID-19.

SELECTION OF CITATIONS
SEARCH DETAIL